Forty Seven 2 website screenshot

Forty Seven 2

Forty Seven, Inc. was a clinical-stage immuno-oncology biopharmaceutical company developing therapies that target cancer immune-evasion pathways, based on technology licensed from Stanford University. Its lead program, magrolimab, was a monoclonal antibody against the CD47 "don't eat me" signal, evaluated in myelodysplastic syndrome, acute myeloid leukemia, non-Hodgkin lymphoma, and solid tumors. Seeded by Lightspeed Venture Partners in 2015, the company completed an IPO in 2018 and was acquired by Gilead Sciences in 2020 for approximately $4.9 billion, becoming a wholly-owned Gilead subsidiary. As a therapeutics developer it exposes no public developer platform, API, or SDK surface; its former site (fortyseveninc.com) now redirects to gilead.com.

Forty Seven 2 is profiled on the APIs.io network. Tagged areas include Company, Biopharmaceutical, Immuno-Oncology, Healthcare, and Clinical Stage.

🌐 Visit website 📡 Source on GitHub
2.2/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-20 · rubric v0.12.0
0 APIs
CompanyBiopharmaceuticalImmuno-OncologyHealthcareClinical StageAcquiredLife Sciences

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-08-20 · rubric v0.12.0
Composite quality — 2.2/100 · minimal
Contract Quality 0.0 / 21
Developer Ergonomics 0.0 / 17
Access Clarity 0.0 / 17
Operational Transparency 0.0 / 11
Contract Governance 0.0 / 10
Discoverability 4.3 / 9
Regulatory Posture 0.0 / 15
Agent readiness — 0/100 · human only
Machine-Readable Contract 0 / 18
Agentic Access Contract 0 / 10
Documented Reversibility 0 / 6
MCP Server 0 / 12
Machine-Readable Auth 0 / 10
Idempotency 0 / 9
Stable Error Semantics 0 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 0 / 7
Typed Event Surface 0 / 6
Agent Skills 0 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
A2A Agent Card 0 / 8
Dry-Run / Simulate Mode 0 / 4
Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.
The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/forty-seven-2: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Resources

Company 2

The organization behind the API

Website
Website
 CrunchBase
CrunchBase

Source (apis.yml)

apis.yml Raw ↑ 
aid: forty-seven-2
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/forty-seven-2.png
name: Forty Seven 2
description: Forty Seven, Inc. was a clinical-stage immuno-oncology biopharmaceutical company developing therapies that target
  cancer immune-evasion pathways, based on technology licensed from Stanford University. Its lead program, magrolimab, was
  a monoclonal antibody against the CD47 "don't eat me" signal, evaluated in myelodysplastic syndrome, acute myeloid leukemia,
  non-Hodgkin lymphoma, and solid tumors. Seeded by Lightspeed Venture Partners in 2015, the company completed an IPO in 2018
  and was acquired by Gilead Sciences in 2020 for approximately $4.9 billion, becoming a wholly-owned Gilead subsidiary. As
  a therapeutics developer it exposes no public developer platform, API, or SDK surface; its former site (fortyseveninc.com)
  now redirects to gilead.com.
url: https://raw.githubusercontent.com/api-evangelist/forty-seven-2/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- lightspeed-venture-partners
x-tier: stub
x-tier-reason: portfolio-lead
x-status: acquired
x-status-note: Acquired by Gilead Sciences in 2020 (~$4.9B); biopharma therapeutics developer with no public API/developer
  surface. The "2" suffix is a portfolio-scraper dedup artifact.
specificationVersion: '0.23'
created: '2026-07-17'
modified: '2026-07-20'
tags:
- Company
- Biopharmaceutical
- Immuno-Oncology
- Healthcare
- Clinical Stage
- Acquired
- Life Sciences
tags_raw:
- Company
- Biopharmaceutical
- Immuno-Oncology
- Healthcare
- Clinical-Stage
- Acquired
- Life Sciences
apis: []
common:
- type: Website
  url: https://www.gilead.com/
- type: CrunchBase
  url: https://www.crunchbase.com/organization/forty-seven-inc
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-20'
  status: nochange
  artifacts_added: 0
  pass: local-v1